{"id":"NCT00641719","sponsor":"Eli Lilly and Company","briefTitle":"A Long-term Study for the Treatment of Painful Diabetic Neuropathy","officialTitle":"A Superiority Study of LY248686 Versus Placebo in the Treatment of Patients With Diabetic Peripheral Neuropathic Pain - Extension Phase","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2008-03","primaryCompletion":"2010-03","completion":"2010-03","firstPosted":"2008-03-24","resultsPosted":"2011-03-31","lastUpdate":"2011-03-31"},"enrollment":258,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"NONE","primaryPurpose":"TREATMENT"},"conditions":["Diabetic Neuropathies"],"interventions":[{"type":"DRUG","name":"Duloxetine hydrochloride","otherNames":["LY248686","Cymbalta"]},{"type":"DRUG","name":"Duloxetine hydrochloride","otherNames":["LY248686","Cymbalta"]}],"arms":[{"label":"Duloxetine 40 mg","type":"EXPERIMENTAL"},{"label":"Duloxetine 60 mg","type":"EXPERIMENTAL"}],"summary":"The purpose of the study is to investigate safety and efficacy of duloxetine for patients with painful diabetic neuropathy at long-term use.","primaryOutcome":{"measure":"Number of Participants Who Experienced an Adverse Event (AE)","timeFrame":"baseline through 1 year","effectByArm":[{"arm":"Duloxetine 40 mg","deltaMin":11,"sd":null},{"arm":"Duloxetine 60 mg","deltaMin":22,"sd":null}],"pValues":[]},"eligibility":{"minAge":"20 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":4,"exclusionCount":3},"locations":{"siteCount":25,"countries":["Japan"]},"refs":{"pmids":["26816607"],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":11,"n":129},"commonTop":["Nasopharyngitis","Glycosylated haemoglobin increased","Somnolence","Constipation","Nausea"]}}